Child Psychiatry and Human Development

, Volume 39, Issue 3, pp 237–245

A Double-blind Placebo Controlled Trial of Piracetam Added to Risperidone in Patients with Autistic Disorder

Authors

    • Psychiatric Research Center, Roozbeh Psychiatric HospitalTehran University of Medical Sciences
  • Hamid Tajdar
    • Psychiatric Research Center, Roozbeh Psychiatric HospitalTehran University of Medical Sciences
  • Mohammad-Reza Mohammadi
    • Psychiatric Research Center, Roozbeh Psychiatric HospitalTehran University of Medical Sciences
  • Mohammad Mohammadi
    • Faculty of MedicineAzad University
  • Gholam-Hossein Nouroozinejad
    • Department of PsychiatryJondi Shapour University of Medical Sciences
  • Omid L. Shabstari
    • Reproductive Biology, Biotechnology and Infertility Research CenterAvesina Research Institute
  • Hossein-Ali Ghelichnia
    • Department of Neurology, Faculty of MedicineTehran University of Medical Sciences
Original Paper

DOI: 10.1007/s10578-007-0084-3

Cite this article as:
Akhondzadeh, S., Tajdar, H., Mohammadi, M. et al. Child Psychiatry Hum Dev (2008) 39: 237. doi:10.1007/s10578-007-0084-3

Abstract

It has been reported that autism is a hypoglutamatergic disorder. Therefore, it was of interest to assess the efficacy of piracetam, a positive modulator of AMPA-sensitive glutamate receptors in autistic disorder. About 40 children between the ages three and 11 years (inclusive) with a DSM IV clinical diagnosis of autism and who were outpatients from a specialty clinic for children were recruited. The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients were randomly allocated to piracetam + risperidone (Group A) or placebo + risperidone (Group B) for a 10-week, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 2 mg/day for children between 10 and 40 kg and 3 mg/day for children weighting above 40 kg. The dose of piracetam was titrated up to 800 mg/day. Patients were assessed at baseline and after 2, 4, 6, 8 and 10 weeks of starting medication. The measure of the outcome was the Aberrant Behavior Checklist-Community (ABC-C) Rating Scale (total score). The ABC-C Rating Scale scores improved with piracetam. The difference between the two protocols was significant as indicated by the effect of group, the between subjects factor (F = 5.85, d.f. = 1, P = 0.02). The changes at the endpoint compared with baseline were: −11.90 ± 3.79 (mean ± SD) and −5.15 ± 3.04 for group A and B respectively. A significant difference was observed on the change in scores in the ABC-C Rating Scale in week 10 compared with baseline in the two groups (t = 6.017, d.f. = 38, P < 0.0001). The results suggest that a combination of atypical antipsychotic medications and a glutamate agent such as piracetam, might have increase synergistic effects in the treatment of autism.

Keywords

AMPAAutismGlutamatePiracetam

Copyright information

© Springer Science+Business Media, LLC 2007